REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overacti...(ns and their patients . Clinical ...),Health

Clinical trials showed the incidence of dry mouth, and constipation also occurs less frequently in patients on Regurin(R) XL compared to all other antimuscarinic agents, and approximately 50% less than Regurin(R) 20mg twice daily(9,10). In addition, Regurin(R) XL has a low potential for interaction with concomitantly administered medications.(11- 13).

Geoff McMillan, Chief Executive Officer of SEP, said: "As a young Company with a focus on Urology, the launch of Regurin XL is very exciting. Urinary incontinence is a very common and embarrassing problem and we believe that Regurin XL offers significant benefits for patients, their physicians and the health service as a whole."

Regurin(R) XL is licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with OAB.

Exclusive distribution rights in the UK for Regurin(R) XL (trospium chloride), have been granted to Specialty European Pharma Ltd (SEP), a UK based, urology focused, specialty pharmaceutical company by Rottapharm|Madaus.

About Regurin(R) XL

Regurin is trospium chloride, a member of the anti-muscarinic class, used to treat the symptoms of OAB. The efficacy has been well established. Trospium chloride has been recommended by NICE for the second line treatment of UI in women after immediate release oxybutynin(14). Regurin XL has a high selectivity for two receptors in the detrusor muscle, M sub(2) and M sub(3)(15).

Regurin(R) XL is a quaternary amine: as such it is a positively charged molecule that does not cross the blood brain barrier or the blood eye barrier(2,4,7) hence unwanted side effects such as impairment of cognitive function are minimal2-7 - an important consideration especially for the elderly population.

    About Speciality European Pharma
'/>"/>
SOURCE  Speciality European Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related medicine news :

1. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
2. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
3. New Data Presented at AUAs Annual Conference Prove GELNIQUE(TM) (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
4. MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
5. FoodBizDaily.com Announces New Free Report - International Trade Opportunity: The Brazilian Acai Berry
6. Arcadia HealthCares DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care
7. Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
8. Intense Daily Workout May Keep Cancer at Bay
9. Life after chemotherapy: Daily tasks, quality of life may be affected, MU researcher finds
10. U.S. Census Bureau Daily Feature for July 21
11. FertilityAuthority Introduces E-Newsletter, The Daily Shot